Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital

• Autor(a) principal: Reis,Samuel Roosevelt Campos dos
• Data de Publicação: 2013
• Outros Autores: Quixada,Acy Telles de Souza, Nunes,Sammara Tavares, Cid,Danielle Maria Camelo, Souza,Jacqueline Holanda de, Costa,Clara Maria Bastos Eloy da, Silveira,Carolina Bizelli, Cid,David Antonio Camelo, Oliveira,Mariana Fatima Cabral de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000300174
• topic: Leukemia, myelogenous, chronic, BCR-ABL positive/drug therapy; Piperazines/therapeutic use; Medication adherence; Fusion Proteins, bcr-abl/genetic; Treatment outcome

Objetive: The aim of this study was to identify the reasons for failure in adherence to imatinib mesylate treatment in chronic myeloid leukemia. Methods: A retrospective review was performed of 100 non-electronic records of patients with Ph+ chronic myeloid leukemia treated with imatinib mesylate. The study period was from January 2001 to January2011. Data were analyzed by Chi-Square and Correspondence analysis using the Statistical Analysis System software package. Results: At the beginning of treatment 41% of patients were in advanced stages of the disease. The unavailability of the drug (44.8%) and myelotoxicity (25.7%) were the most frequent reasons for interruption. The adherence rate was < 90% in 47% of the cases. The low adherence influenced the cytogenetic response (p-value = 0.020) and molecular response (p-value = 0.001). Very high adherence (> 95%) induced complete cytogenetic response, major cytogenetic response and major molecular response. Conclusion: The population of this study obtained lower-than-expected therapeutic responses compared to other studies.